Journal article
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
Abstract
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 signalling in patients with the disease. The efficacy and safety of tocilizumab and sarilumab, which block the binding of IL-6 to its receptor, have been tested in adults with COVID-19-related acute respiratory illness in randomised trials, with important differences …
Authors
Angriman F; Ferreyro BL; Burry L; Fan E; Ferguson ND; Husain S; Keshavjee SH; Lupia E; Munshi L; Renzi S
Journal
The Lancet Respiratory Medicine, Vol. 9, No. 6, pp. 655–664
Publisher
Elsevier
Publication Date
6 2021
DOI
10.1016/s2213-2600(21)00139-9
ISSN
2213-2600